

S2 Table. Baseline characteristics

	Value
Total patients	520
Age (yr)	71.0±8.6
BMI (kg/m ²)	23.9±3.2
PSA (pre-treatment) (ng/dL)	42.7 (11.5-146.6)
ECOG score 0-1	354 (87.3)
HTN	214 (41.2)
DM	105 (20.2)
Cardiovascular disease	48 (9.2)
Primary treatment	
Radical prostatectomy	97 (18.7)
Radiotherapy	193 (35.2)
Enzalutamide treatment sequence	
Pre-docetaxel	240 (46.2)
Post-docetaxel	280 (53.8)
No. of previous hormone therapy	
0-2	364 (89.2)
3-5	55 (17.8)
Metastasis type	
Bone metastasis only	342 (65.8)
Visceral metastasis only	11 (2.1)
Both bone and visceral metastasis	75 (14.4)
No. of bone metastases	
< 10	277 (53.2)
10-20	79 (15.2)
> 20	60 (11.5)
ISUP GG	
1-3	102 (19.6)
4-5	376 (72.3)
Cycle of enzalutamide	10.8±11.1

Values are presented as mean±SD, median (IQR), or number (%). BMI, body mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; ISUP GG, International Society of Urological Pathology Grade Group; PSA, prostate-specific antigen; SD, standard deviation.